D.A. Davidson & CO. Sells 781 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

D.A. Davidson & CO. lessened its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYFree Report) by 2.6% during the third quarter, HoldingsChannel reports. The firm owned 28,929 shares of the company’s stock after selling 781 shares during the period. D.A. Davidson & CO.’s holdings in Harmony Biosciences were worth $948,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. raised its position in Harmony Biosciences by 15.9% during the second quarter. BlackRock Inc. now owns 5,750,478 shares of the company’s stock valued at $202,359,000 after purchasing an additional 790,338 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Harmony Biosciences by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,003,456 shares of the company’s stock worth $133,023,000 after buying an additional 38,958 shares during the period. State Street Corp increased its stake in shares of Harmony Biosciences by 9.3% during the second quarter. State Street Corp now owns 1,140,934 shares of the company’s stock valued at $40,149,000 after purchasing an additional 97,337 shares in the last quarter. Perceptive Advisors LLC increased its position in Harmony Biosciences by 791.4% during the 2nd quarter. Perceptive Advisors LLC now owns 891,370 shares of the company’s stock valued at $31,367,000 after buying an additional 791,370 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Harmony Biosciences by 43.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 832,027 shares of the company’s stock worth $27,166,000 after purchasing an additional 251,623 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HRMY. Needham & Company LLC reaffirmed a “buy” rating and set a $53.00 price target on shares of Harmony Biosciences in a report on Wednesday, November 1st. Bank of America reissued an “underperform” rating and set a $30.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, January 2nd. The Goldman Sachs Group lifted their price target on shares of Harmony Biosciences from $25.00 to $28.00 and gave the company a “sell” rating in a report on Tuesday, January 9th. Raymond James upped their price objective on Harmony Biosciences from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 1st. Finally, Piper Sandler decreased their price target on shares of Harmony Biosciences from $72.00 to $42.00 and set an “overweight” rating on the stock in a research note on Monday, October 16th. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.00.

View Our Latest Stock Analysis on HRMY

Harmony Biosciences Trading Down 1.2 %

HRMY stock opened at $33.31 on Monday. The company has a quick ratio of 4.07, a current ratio of 4.12 and a debt-to-equity ratio of 0.38. Harmony Biosciences Holdings, Inc. has a 52-week low of $18.61 and a 52-week high of $50.75. The company’s 50-day simple moving average is $32.01 and its 200-day simple moving average is $31.02. The firm has a market cap of $1.95 billion, a P/E ratio of 13.54, a PEG ratio of 0.50 and a beta of 0.73.

About Harmony Biosciences

(Free Report)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Read More

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYFree Report).

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.